QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ na
-- x --
-- x --
-- - --
nm - nm
0
na
1,523
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-affimed-to-neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Affimed (NASDAQ:AFMD) from Buy to Neutral.

 affimed-receives-nasdaq-delisting-notice-trading-to-be-suspended-may-20

Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to ...

 wells-fargo-downgrades-affimed-to-equal-weight-lowers-price-target-to-01

Wells Fargo analyst Yanan Zhu downgrades Affimed (NASDAQ:AFMD) from Overweight to Equal-Weight and lowers the price target f...

 leerink-partners-downgrades-affimed-to-market-perform-lowers-price-target-to-039

Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:AFMD) from Outperform to Market Perform and lowers the p...

 affimed-says-abstract-on-phase-2-luminice-203-study-of-ice-acimtamig-in-combination-with-ab-101-accepted-for-oral-presentation-at-asco-2025

MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"),...

 affimed-receives-nasdaq-notice-over-low-share-price-has-until-october-to-regain-compliance

Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to ...

 affimed-reports-results-for-cancer-therapy-in-nsclc-patients

Affimed N.V. (NASDAQ:AFMD) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to...

 wells-fargo-maintains-overweight-on-affimed-lowers-price-target-to-15

Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:AFMD) with a Overweight and lowers the price target from $20 to $15.

 hc-wainwright--co-reiterates-buy-on-affimed-maintains-10-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION